Utilizing of 4-(benzothiazol-2-yl)phenylamine as a precursor of bioactive agents
| dc.Affiliation | October University for modern sciences and Arts (MSA) | |
| dc.contributor.author | A.Shaaban, Mohamed | |
| dc.contributor.author | M.Al Badry, Ossama | |
| dc.contributor.author | M.Kamal, Aliaa | |
| dc.contributor.author | A.Abd El-Gawad, Mohamd | |
| dc.date.accessioned | 2019-10-21T07:19:31Z | |
| dc.date.available | 2019-10-21T07:19:31Z | |
| dc.date.issued | 2012 | |
| dc.description.abstract | Several heterocyclic compounds show either anticancer or antimicrobial activity, the intial goal of this study was directed towards combining some of those heterocyclic moieties- that have either activity- together to test whether the newly formed compounds will demonstrate both activity or one activity will predominate over the other or both activity will deminish. This was accomplished via Scheme 1 and Scheme 2 where diazotization of 4-(benzothiazol-2-yl)phenylamine 1 followed by reacting this functionalized hydrazone with a variety of binucleophiles to give the key intermediates that reacted with amino reagents viz. hydrazine, urea or thiourea to yield some of the goal compounds (Scheme 1). Reacting compound 1with carbonyl or isothiocyanate reagents followed by cyclization of the given key intermediates afforeded a set of novel target compounds (Scheme 2). These final compunds were tested for in vitro antimicrobial and anticancer activity. Two compounds showed both antimicrobial and anticancer activity while the other compounds were highly active either as antimicrobial only or as anticancer only. | en_US |
| dc.description.sponsorship | Organic CHEMISTRY | en_US |
| dc.identifier.citation | [1] T.D.Bradshaw, M.F.G.Stevens, A.D.Westwell; Current Med.Chem., 8, 203-210 (2001). [2] A.Monks, E.Harris, C.Hose, J.Connelly, E.A.Sausville; Molecular Pharmacology, 63, 766- 772 (2003). [3] E.Brantley, V.Trapani, M.C.Alley, C.D.Hose, T.D.Bradshaw, M.F.G.Stevens, E.A.Sausville, S.F.Stinson; DrugMetabolismandDisposition, 32, 1392-1401 (2004). [4] A.Waliqvist, J.Connelly, E.A.Sausville,D.G.Covell, A.Monks; Molecular Pharmacology, 69, 737-748 (2006). [5] C.O.Leong, M.Suggitt, D.J.Swaine, M.C.Bibby, M.F.G.Stevens, T.D.Bradshaw; Molecular Cancer Therapeutics, 3, 1585-1592 (2004). [6] Y.W.Chen, J.E.Cleaver, F.Hanaoka, C.F.Chang; K.Chou; Molecular Cancer Research, 4, 257-265 (2006). [7] E.L.Luzina, A.V.Popov; Eur.J.Med.Chem., 44, 4944-4953 (2009). [8] B.Soni, M.S.Ranawat, R.Sharma, A.Bhandari, S.Sharma; Eur.J.Med.Chem., 45, 2938-2942 (2010). [9] S.Bondock,W.Fadaly,M.A.Metwally; Eur.J.Med. Chem., 45, 3692-3701 (2010). [10] S.Bondock,W.Fadaly,M.A.Metwally; Eur.J.Med. Chem., 44, 4813-4818 (2009). [11] A.E.Rashad, A.H.Shamroukh, M.I.Hegab, H.M.Awad; Acta Chim.Slov., 52, 429-434 (2005). [12] M.Cacic, M.Trkovnik, F.Cacic, E.H.Schon; Molecules, 11, 134-147 (2006). [13] N.Agarwal, P.Srivastava, S.K.Raghuwanshi, D.N.Upadhyay, S.Smha, P.K.Shukia, V.Ram; J.Bioorg.Med.Chem., 10, 869-874 (2002). [14] P.Sharma,A.Kumar,M.Sharma; Eur.J.Med.Chem., 41, 833-840 (2006). [15] P.Vicini, A.Geronikaki, K.Anastasia, M.Incerti, F.Zam; Bioorg.Med.Chem., 14, 3859-3864 (2006). [16] S.Bondock, W.Khalifa, A.A.Fadda; Eur.J.Med. Chem., 42, 948-954 (2007). [17] V.Patil, K.Tilekar, S.Mehendale-Munj, R.Mohan, C.S.Ramaa; Eur.J.Med.Chem., 45, 4539-4544 (2010). [18] D.Havrylyuk, L.Mosula, B.Zimenkovsky, O.Vasylenko,A.Gzella,R.Lesyk; Eur.J.Med.Chem., 45, 5012-5021 (2010). [19] T.Kline, K.C.Barry, S.R.Jackson, H.B.Felise, H.V.Nguyen, S.I.Miller; Bioorg.Med.Chem.Lett., 19, 1340-1343 (2009). [20] S.P.Mohammed; Bull.Fac.Pharm.Cairo Uinv., 37, 33-40 (1999). [21] S.E.Abbas, M.M.Hanna, A.H.Abou Sier, M.A.H.Ramadan; Egypt J.Pharm.Sci., 34, 195-205 (1993). [22] B.Kahveci, O.Bekircan, S.A.Karaoghlu; Indain J.Chem.B, 44b, 2614-2617 (2005). [23] O.Pintilie, L.Profire,V.Sunel,M.Popa,A.Pui;Molecules, 12, 103-113 (2007). [24] M.A.Shaaban, O.M.Al Badry, A.M.Kamal, M.A.W.Abd El-Gawad; J.Chem.Reseach, 4, 715- 718 (2008). [25] G.Bruno, L.Costantino, C.Curinga, R.Maccari, F.Monforte, F.Nicolo , R.Ottana , M.G.Vigoritac; Bioorg.Med.Chem., 10, 1077-1084 (2002). [26] R.Ottana , R.Maccari, M.L.Barreca, G.Bruno, A.Rotondo, A.Rossi, G.Chiricosta, R.Di Paola, L.Sautebin, S.Cuzzocrea, M.G.Vigorita; Bioorg. Med.Chem., 13, 4243-4252 (2005). [27] T.O.Richardson,V.P.Shambhag, K.Adair, S.Smith; J.Heterocyclic Chem., 35, 1301 (1998). | en_US |
| dc.identifier.doi | https://doi.org/ | |
| dc.identifier.issn | 0974 - 7516 | |
| dc.identifier.other | https://doi.org/ | |
| dc.identifier.uri | https://t.ly/WE9rm | |
| dc.language.iso | en | en_US |
| dc.publisher | Organic CHEMISTRY | en_US |
| dc.relation.ispartofseries | Organic CHEMISTRY;Volume 8 Issue 9 | |
| dc.subject | benzothiazol | en_US |
| dc.subject | phenylamine | en_US |
| dc.subject | Pharmacophores | en_US |
| dc.subject | Anticancer | en_US |
| dc.subject | Antimicrobial | en_US |
| dc.subject | Improving chemotherapy regimen design | en_US |
| dc.title | Utilizing of 4-(benzothiazol-2-yl)phenylamine as a precursor of bioactive agents | en_US |
| dc.type | Article | en_US |